1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Qiagen Expands Partnership with Astrazeneca to Develop and Commercialize QIAstat-Dx

02 Sep 2024
Admin
News Article

Qiagen Expands Partnership with Astrazeneca to Develop and Commercialize QIAstat-Dx

Qiagen expands partnership with AstraZeneca to develop and commercialize companion diagnostics, QIAstat-Dx

Overview

Qiagen, a leading global provider of Sample to Insight solutions, announced the expansion of its Master Collaboration Agreement with AstraZeneca to develop and commercialize companion diagnostics (CDx) for AstraZeneca’s future therapies being developed to address chronic diseases.

Terms of Agreement

Under the agreement, Qiagen will develop and validate a genotyping assay using Qiagen’s syndromic testing platform QIAstat-Dx.
The test will enable specialty care providers to potentially perform genotyping whilst patients are undergoing routine clinical examination, thus enabling fast decision making for potential suitability for AstraZeneca’s genomically targeted medicines.

Words from SVP: Qiagen

“We are pleased to expand our partnership with AstraZeneca into new disease areas using our QIAstat-Dx system and to develop together the first companion diagnostic for chronic diseases based on this platform”, said Fernando Beils, senior vice president, head of the molecular diagnostics business area at Qiagen.
“The development of the QIAstat-Dx genotyping assay with AstraZeneca showcases Qiagen’s expertise in companion diagnostic development and commercialization, utilizing the most suitable molecular testing platform to meet the unique clinical and commercial needs of patient testing.”

The QIAstat-Dx System

The QIAstat-Dx system, designed for laboratory use, employs cost-efficient, single-use cartridges with built-in sample processing and on-board reagents.
Utilizing multiplex real-time PCR, it detects and differentiates between multiple biomarkers, with results in about an hour.
QIAstat-Dx also provides easy-to-view cycle threshold (Ct) values and amplification curves, offering additional insights not available with end-point PCR or other techniques.
At the end of 2023, over 4,000 cumulative instrument placements had been made.
About Qiagen
Qiagen is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics.
These can detect genetic abnormalities to provide insights that guide clinical decision-making about treatments. From polymerase chain reaction (PCR) and digital PCR (dPCR) to next-generation sequencing (NGS), Qiagen offers an unmatched breadth of technologies, which means it can tailor products to partners’ needs.

Development and Commercialization of Companion Diagnostics

Qiagen has master collaboration agreements to develop and commercialize companion diagnostics with more than 30 global companies – a deep pipeline that will advance precision medicine, which tailors a patient’s treatment to the genetic profile identified by companion diagnostics testing.
Furthermore, Qiagen has a series of collaborations with Neuron23 and Helix to develop companion diagnostics in disease areas outside oncology.

About Qiagen N.V.

Qiagen N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life.